Friday June 29, 12:51 pm Eastern Time
Press Release
Illumina Signs Genotyping Services Agreement With
GlaxoSmithKline
SNP Scoring Service to Leverage Illumina's BeadArray Platform Technology
SAN DIEGO--(BW HealthWire)--June 29, 2001--Illumina, Inc. announced today that it has signed a
commercial agreement with GlaxoSmithKline (GSK) to provide single nucleotide polymorphism (SNP)
genotyping services on a sample collection provided by GSK. Under the terms of the agreement, Illumina
will use its BeadArray(TM) technology to ``score,'' or determine the frequency of specified SNPs in the
sample set. Further details were not disclosed. (snip)
Friday June 29, 2:00 am Eastern Time
Press Release
SOURCE: Orchid BioSciences, Inc.
Orchid Completes First Major Milestone for AstraZeneca
PRINCETON, N.J., June 29 /PRNewswire/ -- Orchid BioSciences, Inc. (Nasdaq: ORCH - news) today
announced that it has successfully completed the first milestone in its multi-year genotyping and
pharmacogenetics collaboration with AstraZeneca, resulting in a significant payment to Orchid. Further
financial details were not disclosed.
Using the SNPcode(TM) technology that combines Orchid's proprietary SNP-IT(TM) biochemistries
with the GenFlex(TM) chip and GeneChip® system of Affymetrix, Orchid rapidly developed assays and
conducted genotyping for the first cohort of samples provided by AstraZeneca. In a significant
concordance study to validate the overall accuracy and reproducibility of the technology, Orchid has also
exceeded all of the targets established for the first phase of the program. Based on these positive results,
Orchid and AstraZeneca are now proceeding to the next phase of the collaboration. (snip) |
